Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence/Machine Learning Tools for Improved Assessment in Biomedical and Behavioral Research

Funding Agency:
National Institutes of Health
The purpose of this Notice of Special Interest (NOSI) is to encourage grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence/machine learning (AI/ML) tools and technologies in biomedical and behavioral research. The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI/ML algorithms.

Research supported by this NOSI is expected to provide support for analytical and/or clinical validation of recently developed digital health and AI/ML technologies. Digital health and AI/ML technologies are defined broadly to include any health technology leveraging mobile health, health information technology, wearable devices, sensors, telehealth and telemedicine, internet of things (IoT), SaMD and/or related AI/ML algorithms and tools to monitor and manage health across the life course. As noted previously, the purpose of this NOSI is not to support the development of new tools or technologies.

Applicants should clearly justify the importance and implications of validating digital health and AI/ML tools and technologies. Studies should apply rigorous research methods to evaluate the analytical and/or clinical validity of any proposed digital health and AI/ML applications including the use of gold-standard comparators. Projects that validate digital health or AI/ML tools for a new context of use, including another disease area or specific populations (e.g., low income, minority group), and research projects that evaluate the reliability of the tool and its sensitivity are encouraged.

Studies proposing secondary analysis should address the sufficiency of existing datasets to validate technologies and deepen the evidence base of digital health and AI/ML applications while also addressing potential bias, including plans for risk mitigation that ensure safety, privacy, and effectiveness among diverse individuals and populations.  For Food and Drug Administration (FDA) regulated devices, activities included under this notice should follow FDA guidance and support appropriate activities leading to a future marketing submission to the FDA.

Investigators must carefully review the specific research interests of NIH Institutes and Centers (ICs) that are participating in this NOSI.

This notice applies to due dates on or after April 05, 2024, and subsequent receipt dates through July 06, 2025. This NOSI expires on July 06, 2025.





Engineering and Physical Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

April 5, 2024